Applied Therapeutics Announces Launch of Galactosemia Awareness and Education Initiative

IndustryPRwire -- Applied Therapeutics announced the launch of Galactosemia Together, the first and only industry-led Galactosemia awareness and education campaign. Developed in partnership with the Galactosemia community, this initiative aims to address gaps in education by providing updated, reliable and credible resources to help connect, educate and support those families impacted by this disease.

Brittany Cudzilo, Outreach Coordinator, Board of Directors for the Galactosemia Foundation Commented “We are thrilled that Applied Therapeutics is not only providing hope for a drug that could be used in the treatment of Galactosemia, but also is committed to creating valuable resources in the realm of disorder awareness and education. It is vital that patients have access to educational materials that help them understand the disorder so that they can make informed decisions, with the help of their medical team in regard to their care, On behalf of the Foundation, I’d like to thank Applied Therapeutics for their commitment to the Galactosemia community.”

Shoshana Shendelman, PhD, Founder, CEO and Chair of the Board of Applied Therapeutics Commented “We are pleased to partner with the Galactosemia community in this important educational endeavor, Applied Therapeutics is committed to supporting the needs of Galactosemia patients and caregivers.”

Galactosemia is a rare, slowly progressing metabolic disease caused by a genetic inability to break down the sugar galactose. Aldose Reductase (AR), an enzyme known to play a role in many diseases including Galactosemia, converts galactose into galactitol, a toxic metabolite that builds up in tissues and organs and can cause long-term disease complications. There are approximately 3,000 individuals with Galactosemia in the U.S. and about 3,500 individuals in the E.U. Most patients with Galactosemia are under the age of 40, as newborn screening was not widely adopted until the 1980s. Galactosemia is now included as part of routine newborn screening in all 50 U.S. states, and in many countries in Europe.

Related Posts

Subscribe Our Newsletter